Integrating Electroporation Know-how & DNA Vaccine Platforms
HONG KONG SAR – Media OutReach – 20 September 2022 – Immuno Remedy BioTech, a scientific stage biotechnology group based mostly within the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, introduced in the present day the acquisition of 92.6% of Shanghai Teresa Healthcare, the pioneer of electroporation know-how and system in China. The transaction can be settled in money and shares. Teresa’s shareholders will swap for about 1.5% fairness in Immuno Remedy whereas the inventor of Teresa’s EP know-how, Professor XU Yuhong (徐宇虹), maintains her 7.4% direct fairness in Teresa.
Teresa EP system delivers temporary electrical pulses to advertise environment friendly penetration of DNA vaccine via cell membrane for the enhancement of gene expression and supreme immune responses. It’s the solely such system authorised by Nationwide Medical Merchandise Administration for the administration of DNA vaccine in China. Such EP know-how has been an integral a part of Immuno Remedy’s DNA vaccine supply technique from analysis to scientific stage.
Based in 2004, Shanghai Teresa is an revolutionary medical system group focusing in electro immunotherapies and rehabilitation therapies. In 2005, Teresa’s electroporation know-how was developed to boost the supply of DNA drugs, based mostly on the mental property generated by Shanghai Jiao Tong College beneath the Nationwide 863 Challenge. Such EP know-how has been confirmed protected and efficacious after deployment of over 10,000 instances in collaboration with greater than thirty hospitals for the administration of DNA drugs in quite a few human trial topics.
Immuno Remedy has two PD-1-Enhanced DNA vaccines at present in section 1 scientific trial for prevention of COVID-19 and therapeutic remedy of HIV/AIDS.
Dr JIN Xia, CEO of Immuno Remedy mentioned, “Immuno Remedy has partnered with Teresa over time in creating customised EP supply technique for our PD-1-Enhanced DNA vaccines, which has led to encouraging ends in scientific setting just lately. I’m happy with this convergence with Teresa, which can little question carry our groups even nearer collectively. Teresa will proceed to function independently whereas leveraging on Immuno Remedy’s R&D platform for the event of their subsequent technology non-invasive EP know-how for intradermal supply technique. Immuno Remedy is dedicated to help the continuous development and success of Teresa.”
Ms. CHEN Liye, CEO of Teresa mentioned, “Based on our long run collaboration, Teresa is worked up to turn out to be a member of Immuno Remedy Group. This transfer won’t solely present us with a a lot nearer R&D relationship, which is important for our know-how development but in addition provide us the monetary functionality to satisfy future wants. Teresa treasures our collaborations with different gamers within the discipline and sit up for persevering with our collaborations with new and sustainable EP know-how.”
Professor CHEN Zhiwei, Director of AIDS Institute on the College of Hong Kong and the Principal Scientific Advisor of Immuno Remedy mentioned, “Our analysis and improvement work on the AIDS Institute and Immuno Remedy has benefitted from Teresa’s EP know-how and their diligent collaborative effort over the previous 12 years. I’m happy to see their relationship creating into a good nearer tie. Look ahead to the event of the following technology of EP know-how for additional optimisation of supply technique and affected person expertise.”
Dr Percy CHENG, Chairman of Immuno Remedy concludes, “This transaction provides Immuno Remedy the chance to safe Teresa’s EP know-how for help of not solely R&D but in addition the scientific administration of our PD-1-Enhanced DNA vaccines. We’re happy with Professor XU’s choice to stay as our co-investor in Teresa and are optimistic in the way forward for EP know-how in our DNA vaccine improvement.”Hashtag: #ImmunoCureBiotech
The issuer is solely liable for the content material of this announcement.
Immuno Remedy BioTech
Immuno Remedy BioTech is a scientific stage biotechnology group based mostly within the Hong Kong Science Park, specializing in analysis and improvement of vaccines and immunotherapies for cancers, inflammatory and infectious ailments based mostly on its patented PD-1-Enhanced DNA vaccine and Anti-Δ42PD1 Blocking Antibody know-how platforms.
To be taught extra about Immuno Remedy BioTech, please go to 
www.immunocure.hk
Shanghai Teresa Healthcare
Based in 2004, Shanghai Teresa is an revolutionary medical system group based mostly in Shanghai Zhangjiang Hello-Tech Park, focusing in electro immunotherapies and rehabilitation therapies.
To be taught extra about Shanghai Teresa Healthcare, please go to http://www.e-teresa.com http://www.teresabio.com
